Gossamer Bio Inc [GOSS] stock is trading at $1.07, up 5.94%. An important factor to consider is whether the stock is rising or falling in short-term value. The GOSS shares have gain 11.46% over the last week, with a monthly amount glided 11.38%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Gossamer Bio Inc [NASDAQ: GOSS] stock has seen the most recent analyst activity on June 25, 2024, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $9. On July 27, 2023, downgrade downgraded it’s rating to Neutral and revised its price target to $1.25 on the stock. Raymond James downgraded its rating to a Mkt Perform. Guggenheim initiated its recommendation with a Neutral. SMBC Nikko downgraded its rating to Neutral for this stock on December 07, 2022, but kept the price target unchanged to $3. In a note dated December 07, 2022, JP Morgan downgraded an Underweight rating on this stock.
Gossamer Bio Inc [GOSS] stock has fluctuated between $0.45 and $1.60 over the past year. Currently, Wall Street analysts expect the stock to reach $3.75 within the next 12 months. Gossamer Bio Inc [NASDAQ: GOSS] shares were valued at $1.07 at the most recent close of the market. An investor can expect a potential return of 250.47% based on the average GOSS price forecast.
Analyzing the GOSS fundamentals
Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -0.68%, Pretax Profit Margin comes in at -0.74%, and Net Profit Margin reading is -0.79%. To continue investigating profitability, this company’s Return on Assets is posted at -0.22, Equity is -1.17 and Total Capital is -0.21. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of2.44.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.0167 points at the first support level, and at 0.9633 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.1067, and for the 2nd resistance point, it is at 1.1433.
Ratios To Look Out For
For context, Gossamer Bio Inc’s Current Ratio is 8.21. On the other hand, the Quick Ratio is 8.21, and the Cash Ratio is 1.92. Considering the valuation of this stock, the price to sales ratio is 2.53, the price to book ratio is 2.97.
Transactions by insiders
Recent insider trading involved Aranda Richard, Chief Medical Officer, that happened on Jun 24 ’24 when 1908.0 shares were sold. President & CEO, Hasnain Faheem completed a deal on Jun 21 ’24 to buy 0.37 million shares. Meanwhile, COO/CFO Giraudo Bryan bought 100000.0 shares on Jun 18 ’24.
